UK defence medical services guidance for the use of recombinant factor VIIa (rFVIIa) in the deployed military setting.
Use of recombinant Factor VIIa (rFVIIa) for trauma is currently an 'off label' use. There are reports of rFVIIa contributing to the successful outcome of military trauma patients. This paper sets out the current position of the UK Defence Medical Services with regard to using rFVIIa in military trauma.
Hodgetts
T J
TJ
Royal Centre for Defence Medicine, Birmingham. Prof.ADMEM@rcdm.bham.ac.uk
Kirkman
E
E
Mahoney
P F
PF
Russell
R
R
Thomas
R
R
Midwinter
M
M
D015942:Factor VIIa / Q000627:therapeutic use*; D006470:Hemorrhage / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D008887:Military Medicine; D008889:Military Personnel; D011994:Recombinant Proteins / Q000627:therapeutic use; D014218:Triage; D006113:United Kingdom; D014857:Warfare; D014947:Wounds and Injuries / Q000188:drug therapy*
D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa